Eli Lilly's stock has seen a substantial boost, rising over 5% as the company enters negotiations with the Trump administration to improve patient access and lower drug prices. Recent developments include a remarkable 56% revenue increase year-over-year, driven by its successful GLP-1 drugs, Mounjaro and Zepbound. Despite facing criticism regarding its weight-loss drug Foundayo after a liver failure incident, the company continues to thrive with an optimistic revenue forecast. Eli Lilly has also made significant acquisitions—most notably, a $7 billion deal for Kelonia Therapeutics—to enhance its oncology pipeline and a $2.3 billion acquisition of Ajax Therapeutics to solidify its weight-loss strategy. The launch of Foundayo marks a pivotal expansion in the competitive obesity drug market, supported by partnerships for distribution and strong sales expectations.
Click a month on the chart to update the report below.
.jpg&width=160)